SCMP


Maxim Comments On Sucampo Following Paragraph IV Certification Notice

In a research report released Friday, Maxim Group analyst Jason Kolbert maintained a Buy rating on Sucampo (NASDAQ:SCMP) with a $15 price target, …

Maxim Group Raises Sucampo Price Target On The Back Of Double Digit Growth For Amitiza

In a research report released today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Sucampo (NASDAQ:SCMP) and raised his price target …

Cantor Raises Sucampo Price Target To $14, As Takeda Continues To Invest in Amitiza

In a research note issued to investors today, Cantor analyst Irina Rivkind assigned a Buy rating on Sucampo (NASDAQ:SCMP) and raised her price target to $14 …

Roth Capital Doubles Sucampo Price Target On Updated Amitiza Revenue Build

In a report sent to investors today, analyst Ed Arce of Roth Capital maintained a Buy rating on Sucampo (NASDAQ:SCMP) and raised his price target to $18 (from …

Roth Capital Affirms Buy On Sucampo Following Agreement Extension With Takeda

In a research report released Wednesday, Roth Capital analyst Ed Arce Affirmed a Buy rating on Sucampo (NASDAQ:SCMP) with a $9 price target, as the company extended its …

Maxim Group Upgrades Sucampo Pharmaceuticals To Buy, Increases PT To $10

In a research note published today, Maxim Group analyst Jason Kolbert upgraded shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) from a Hold rating to a Buy …

Favorable Patent Settlement With Par – A Strong Win For Sucampo, Says Roth Capital

In a research report released to investors today, analyst Ed Arce of Roth Capital reiterated a Buy rating on Sucampo (NASDAQ:SCMP) with a $9.00 price …

Roth Capital Maintains Buy On Sucampo Following The Launch Of Amitiza DTC Campaign

In a research report issued today, Roth Capital analyst Ed Arce maintained a Buy rating on Sucampo (NASDAQ:SCMP) with a $9 price target, following the company’s …

Cantor Fitzgerald Reiterates Buy On Sucampo Following 2Q14 Results; Keeps $12 PT

In a research note released yesterday, Cantor Fitzgerald analyst Irina Rivkind reiterated a Buy rating on Sucampo Pharmaceuticals (SCMP) with a $12 price target, following the company’s second …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts